Technology
Technological Innovations
We are dedicated to continuous innovation in core siRNA pharmaceutical technologies.
Our RiboGalSTARTM liver-targeting delivery platform enables precise and effective delivery to hepatic tissues. Building on this success, RiboOncoSTARTM, our first extrahepatic delivery technology, offers targeted delivery to a variety of tumor tissues.
Expanding beyond the liver, RiboPepSTARTM represents a comprehensive platform for targeted delivery to other organs and tissues. We have identified promising candidate molecules targeting the kidneys, central nervous system (CNS), adipose tissue, and muscle.
In parallel, we have made significant advancements in our siRNA chemical modification platform and multi-target drug development platform, further enhancing the efficacy, specificity, and therapeutic potential of our oligonucleotide drugs.
-
-
RiboGalSTARTM
Our liver-targeting RiboGalSTARTM delivery technology enables siRNA delivery to various hepatic targets for relevant indications.
Our RiboGalSTARTM platform has advanced six programs into clinical development. Its high potency, prolonged duration, and favorable safety profile are clinically validated. This marks it as one of the most productive GalNAc platforms globally, with patents secured in major jurisdictions, including China, Europe, and the United States.
-
RiboOncoSTARTM
We are developing RiboOncoSTARTM, a leading tumor-targeted platform leveraging oligonucleotide-conjugate delivery technology, to support our development of multiple potentially first-in-class cancer treatments.
In preclinical studies, RiboOncoSTARTM has demonstrated superior anti-tumor effects and safety profiles in selected cancer (including glioma, pancreatic cancer) versus standard-of-care treatments.
-
RiboPepSTARTM
RiboPepSTARTM is Ribo’s delivery technology achieves extrahepatic organ targeting via molecular conjugation.
The platform shows efficacy exceeding existing therapies in preclinical models for renal and CNS delivery. Combined with its favorable safety profile, this positions us at siRNA innovation's global forefront.
-
-
-
Chemical Modification Platform
Our proprietary RSC (Ribo Stabilization Chemistry) platform is a proprietary iterative siRNA chemical modification technology platform based on systematic studies of siRNA degradation mechanism, sequence activity, off-target rules and durability.
The synergy between RSC and our RiboGalSTARTM delivery technology is demonstrated by the favorable safety profile and sustained efficacy of RBD4059 and other clinical-stage assets.
-
-
-
Multi-Target Drug Development Platform
Unlike single-target siRNA drugs, our multi-target platform enables simultaneous interference with ≥2 targets within a single drug molecule, achieving synergy through combinatorial targeting at adjustable ratios–a key technological advantage.
-
-
-
Model-Informed Drug Development（MIDD）Platform
Leveraging on our in-house capacity for modeling and simulation techniques, we perform quantitative analysis of drug-disease data to gain mechanistic insights into siRNA action and enhance predictive accuracy throughout drug development stages.
-
-
-
siRNA Sequence Design and Screening Platform
We have developed our own proprietary software for the design of siRNA sequences.
This platform enables rapid identification of high-quality siRNA candidates by analyzing key parameters such as off-target gene prediction, cross-species comparison, and sequence homology. It ensures optimal specificity and activity in selected sequences.
Complementing this, our high-throughput screening platform efficiently generates and evaluates lead oligonucleotide compounds, accelerating the discovery and optimization process.
-